Katie Falloon, MD: Studying IBD-Associated Peripheral Arthritis
Falloon said IBD-associated peripheral arthritis is common, but not well understood.
Kendall Beck, MD: Promising New Tofacitinib Data From the Crohn's and Colitis Congress
Dose de-escalation of tofacitinib resulted in less hospitalizations for patients with ulcerative colitis.
Laura E. Raffals, MD: Sifting Through All the Drug Choices for IBD
The potential for personalized medicine in inflammatory bowel disease might. be realized in the next few years.
Adopting Greater CPR Strategies After Damar Hamlin
Michael J. Ackerman, MD, PhD, discusses the simplicity and availability of education around CPR and defibrillator use, and the role of clinicians in raising public health preparedness.
Damar Hamlin and the Commonality of Cardiac Arrest Emergencies
A Mayo Clinic cardiologist discusses the national variability in CPR and AED access, and the actions that saved Hamlin's life during Monday Night Football.
A Reflection on the Limitation of Reproductive Health Rights in 2022
A maternal-fetal medicine physician discusses plans for improvements in 2023.
Daniel W. Coyne, MD: The Need for New CKD Treatments
With the population aging, there is a need for new treatments in nephrology.
The Benign Hematology Patient Journey
Harold Bays, MD: Considering the Future of Anti-Obesity Medications
A continued discussion with Dr. Bays on anti-obesity therapies down the line and where they might be in the near future.
Harold Bays, MD: Transforming Obesity Management with Highly Effective Therapies
Anti-obesity medications have the potential for significant weight reduction, but the development of newer agents may lead to an even greater change in obesity care.
Why Many Smokers Fail to Quit on Their First Attempt
American Lung Association's Jennifer Folkenroth discusses the issues with "cold turkey," and what every habitual smoker should look for in a cessation plan.
Why Health Care Was Unprepared for the 2022 RSV Surge
A pediatric emergency medicine physician discusses the epidemic factors that still perturb experts, and the status of vaccination and treatment strategies.
2022: The Year of JAK Inhibitors
Brett King, MD, PhD, reviews how the drug class has altered the state of chronic skin disease management in this year alone.
Brett King, MD, PhD: Following Up the Ruxolitinib Cream Approval for Vitiligo
Why patience is key following the major FDA decision earlier this year.
Bruce Sands, MD, MS: Guselkumab Data Continues to Impress at ACG
In the QUSAR study, 80% of patients treated with guselkumab achieved a clinical response.
David R. Lally, MD: What Led to the GATHER Trials for Avacincaptad Pegol
A review of the development of complement inhibitors and how the latest GATHER2 data support avacincaptad pegol for the treatment of geographic atrophy.
Sevag Demirjian, MD: Improving Dialysis for ICU Patients
Dr. Demirjian explained suggested changes to how dialysis is conducted in hospital settings.
Samir Parikh, MD: A Promising New Treatment for Lupus Nephritis
There are plans for a larger sized study testing zetomipzomib in patients with lupus nephritis.
Cynthia Silva, MD: Improving At Home Dialysis
With the population aging, there is a need for more home environmental treatment options for patients with kidney disease.
Simon Hsu, MD, MS: Are Vitamin D Metabolites a Biomarker for Cardiovascular Disease?
The study shows vitamin D levels do not necessarily forecast the risk of cardiovascular disease in patients with chronic kidney disease.
Ester Oh, PhD: Sex Differences in Cardiovascular Disease Risk for Chronic Kidney Disease Patients
Females generally have a lower risk of cardiovascular disease compared to males.
Lebrikizumab Maintains Atopic Dermatitis Efficacy Over 1 Year
New phase 3 data shared at Fall Clinical Dermatology show the IL-13 inhibitor maintained skin clearance observed at 16 weeks.
Christopher Bunick, MD, PhD: Following Up on Benzene Exposure Risk
After the announced recall of dry shampoo products by Unilever this month, dermatologists anticipate an uptick in patient concerns.
How To Improve Pediatric Eczema Screening, Prevention
Lawrence Eichenfield, MD, discusses recent achievements in identifying and possibly preventing atopic dermatitis development in infants.
Crisis Point: Insulin Access in the United States
Welcome back to Crisis Point. A special episode focuses on the issue of insulin accessibility and affordability in the United States, with four experts in the diabetes arena weighing in on the topic.
Bincy Abraham, MD: Treating IBD Patients With Upadacitinib
A greater proportion of the upadacitinib 15 mg and upadacitinib 30 mg group achieved clinical remission based on the Crohn’s Disease Activity Index
Evan Dellon, MD, MPH: New Late-Breaking Data on Dupilumab for EoE
Dupilumab represents the first ever approved treatment for EoE.
Paul Feuerstadt, MD: Exciting New Data on RBX2660
If approved by the FDA, RBX2660 would be the first approved live microbiota therapeutic for the treatment of recurrent CDI.
Aasma Shaukat, MD, MPH: The Current State of Colorectal Cancer Screenings
The COVID-19 pandemic has hurt the effort of colorectal cancer screenings.
How Do We Treat Children with Systemic Eczema Therapies?
With dupilumab already available and JAK inhibitors on the way, clinicians have a bevy of treatments designated for pediatric patients.
2 Clarke Drive Cranbury, NJ 08512